Publications by authors named "Joshua Heiber"

Claim this Profile
I
Interleukin-18 (IL-18) engineered for half-life extension and resistance to IL-18 binding protein (IL-18BP) to enhance anti-cancer therapeutic potential.
Kristiana H Dreaden, Su-Ping Pearson, Pinar S Gurel, Robert G Newman, Yanchun Zhao, Joshua F Heiber

Cytokine· September 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
N
Novel engineered IL-2 Nemvaleukin alfa combined with PD1 checkpoint blockade enhances the systemic anti-tumor responses of radiation therapy.
Kewen He, Nahum Puebla-Osorio, Hampartsoum B Barsoumian, Duygu Sezen, Zahid Rafiq, Joshua Heiber

J Exp Clin Cancer Res· September 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
Correction: Novel engineered IL-2 Nemvaleukin alfa combined with PD1 checkpoint blockade enhances the systemic anti-tumor responses of radiation therapy.
Kewen He, Nahum Puebla-Osorio, Hampartsoum B Barsoumian, Duygu Sezen, Zahid Rafq, Joshua Heiber

J Exp Clin Cancer Res· September 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
Anti-CD33 chimeric antigen receptor targeting of acute myeloid leukemia.
Carol O'Hear, Joshua F Heiber, Ingo Schubert, Georg Fey, Terrence L Geiger

Haematologica· March 2015

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Preclinical safety and activity of recombinant VSV-IFN-β in an immunocompetent model of squamous cell carcinoma of the head and neck.
Vittal V S Kurisetty, Joshua Heiber, Rae Myers, Guilherme S Pereira, Jarrard W Goodwin

Head Neck· November 2014

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
Context and location dependence of adaptive Foxp3(+) regulatory T cell formation during immunopathological conditions.
Joshua F Heiber, Terrence L Geiger

Cell Immunol· September 2012

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
E
Evaluation of innate immune signaling pathways in transformed cells.
Joshua F Heiber, Glen N Barber

Methods Mol Biol· January 2012

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Potential of vesicular stomatitis virus as an oncolytic therapy for recurrent and drug-resistant ovarian cancer.
Joshua F Heiber, Xiang-Xi Xu, Glen N Barber

Chin J Cancer· December 2011

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
T
The alpha subunit of eukaryotic initiation factor 2B (eIF2B) is required for eIF2-mediated translational suppression of vesicular stomatitis virus.
Rachel Elsby, Joshua F Heiber, Peter Reid, Scot R Kimball, Graham D Pavitt

J Virol· October 2011

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
V
Vesicular stomatitis virus expressing tumor suppressor p53 is a highly attenuated, potent oncolytic agent.
Joshua F Heiber, Glen N Barber

J Virol· October 2011

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
E
Explicit targeting of transformed cells by VSV in ovarian epithelial tumor-bearing Wv mouse models.
Callinice D Capo-chichi, Toni M Yeasky, Joshua F Heiber, Ying Wang, Glen N Barber

Gynecol Oncol· February 2010

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
V
Vesicular stomatitis virus inhibits mitotic progression and triggers cell death.
Papia Chakraborty, Joachim Seemann, Ram K Mishra, Jen-Hsuan Wei, Lauren Weil, Joshua Heiber

EMBO Rep· October 2009

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis